

Table SII. Summary of previous reports of low-dose total skin electron beam therapy in mycosis fungoides

Study	Patients <i>n</i>	Median age (years)	Median number of prior treatments	Stage	Dose (Gy)	Complete response (%)	Partial response (%)	Overall response (%)	Progression-free survival (months)	Side-effects
Morris, 2017 (20)	103	68	3 (0–5)	IB–IV 54IB 33 IIB 12 III 4 IV	12	18	69	92	11.9	Grade 1: 100% Grade 2: 32% Grade 3: 8% Grade 4: 0%
Elsayad, 2015 (18)	12	56	5 (1–8)	IB–IVB	12–28 (median dose 20)	25	46	71	3	Grade 1: 100% Grade 2: 50% Grade 1–2: 60% 1 superficial CBC
Kramstrup, 2015 (21)	21	66	5 (1–8)	IB–IVA 12 IB 5 IIB 1 IIIA 3 IVA	10	57	38	95	5.8	
Hoppe, 2015 (22)	33	63	4 (1–10)	IB–IIIA 22 IB 2 IIA 7 IIB 2 IIIA	12	27	61	88	16.3	Grade 3: 6% (2 patients) Grade1–2: -
Kamstrup, 2012 (24)	10	62	3 (2–5)	IB–IVA 6 IB 2 IIB 1 IIIA	10	70	20	90	5.2	Grade 1: 70% Grade 2: 30%
Harrison, 2011 (25)	19 51 32	59	1–6	IIVA T2: 7; T3: 8; T4: 4 T2: 25; T3: 14; T4: 12 T2: 19; T3: 7; T4: 6	5–10 10–<20 20–<30	16 35 34	73 63 63	89 98 97	12 25.7 29.3	-
Kamstrup, 2008 (26)	9	68.7	2 (2–6)	IB–IIB	4	22	67	89	2.7	1 patient with 2CBC
Summary	Total of 286 patients	Median age 63	Median prior treatment 3.5	Stage IB–IVB	Median dose 11 11.33	Median 27 33	Median 63 55.55	Median 90 89.88	Median 8.85 Mean 10.3	-